Literature DB >> 19343972

Vitrectorhexis versus forceps capsulorhexis for anterior and posterior capsulotomy in congenital cataract surgery.

Dicle O Hazirolan1, Ugur E Altiparmak, Bekir S Aslan, Sunay Duman.   

Abstract

PURPOSE: To compare the results of anterior and posterior continuous curvilinear capsulorhexis created using forceps with those created using vitrector in eyes suffering from congenital cataract.
METHODS: Twenty-eight eyes with congenital cataract were included in the study. The anterior and posterior continuous curvilinear capsulorhexes were created using microforceps in 17 eyes or through a vitrector in 11 eyes.
RESULTS: Corneal edema (P = .56) and anterior chamber flare (P = 1.0) were comparable in both groups. In addition, the time for optical axis clarity was also similar between the groups (P = .98).
CONCLUSION: The current results suggest that the use of both techniques appears to be equally safe and effective for the achievement of anterior and posterior capsulorhexis.

Entities:  

Mesh:

Year:  2009        PMID: 19343972     DOI: 10.3928/01913913-20090301-12

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  3 in total

1.  Delineating the extent of anterior capsulorhexis with gentian violet using capsulorhexis marker: a preliminary study of efficacy and toxicity in an animal model.

Authors:  Mohamed Abdel Moneim Hassaballa; Amr Abd El-Latif Osman
Journal:  Clin Ophthalmol       Date:  2011-06-17

2.  Vitrectorhexis versus forceps posterior capsulorhexis in pediatric cataract surgery.

Authors:  Lav Kochgaway; Partha Biswas; Ajoy Paul; Sourav Sinha; Rupak Biswas; Puspen Maity; Sumita Banerjee
Journal:  Indian J Ophthalmol       Date:  2013-07       Impact factor: 1.848

3.  Refractive Lens Exchange Combined with Primary Posterior Vitrectorhexis in Highly Myopic Patients.

Authors:  Tarek A Mohamed; Wael Soliman; Dalia M El Sebaity; Ahmed M Fathalla
Journal:  J Ophthalmol       Date:  2017-04-20       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.